An Experimental Study That Investigate Effects of Atreleuton in Metabolic Syndrome

INTRODUCTION: The inflammation, LDL oxidation, and insulin resistance play an important role in the development of metabolic syndrome (MetS). This study aims to investigate the effects of atreleuton on serum lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), leukotriene B4 (LTB-4), insulin, and adipose tissue glucose transporter 4 (GLUT-4) levels in an experimental MetS model in rats.
METHODS: The rats were randomly divided into 3 groups: Group 1 (control, n = 7); Group 2 (MetS group, n = 8), Group 3 (MetS + atreleuton administered group, atreleuton (25 mg/kg/day) was administrated orally by gavage during the last 4 weeks of the experiment). MetS was created by feeding rats with high fructose and fat diet for 10 weeks in groups 2 and 3. Measurements of test parameters were made by ELISA method.
RESULTS: The atreleuton caused a significant decrease in levels of serum LTB-4, LOX-1, insulin, and homeostatic model assessment for insulin resistance (HOMA-IR), while significantly increase on quantitative insulin sensitivity check index (QUICKI). However, atreleuton did not cause a significant change in tissue GLUT-4 level.
DISCUSSION AND CONCLUSION: The results of this study suggest that atrelutone may be a protective agent against MetS complications by decreasing the levels of LTB-4 and LOX-1 that play an important role in MetS pathogenesis. Besides, the effect of atreleuton on the tissue GLUT-4 pathway needs to be supported by further studies.